Biological
Measles-Mumps-Rubella Vaccine clinical trials
- studies test it
- 32
- open now
- 2
- in phase 3
- 16
- first study started
- 2000
Keep track of what changes. Save the Measles-Mumps-Rubella Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2020 | 4 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 16
- Phase 4
- 11
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Measles
- 12
Who runs them
Industry 20 · Other 12
GlaxoSmithKline (12) · Sanofi Pasteur, a Sanofi Company (3) · Assiut University (2) · Josefin Eklöf (1) · Sinovac Biotech Co., Ltd (1) · Liaoning Chengda Biotechnology CO., LTD (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Themis Bioscience GmbH (1)
Often tested with
Tested in the same studies.
Chickenpox Vaccine (3) · Meningococcal Vaccines (2) · Rotavirus Vaccines (2) · BCG Vaccine (1) · Poliovirus Vaccine, Inactivated (1) · 13-valent pneumococcal vaccine (1) · Vitamin D (1) · Japanese encephalitis live attenuated strain SA 14-14-2 antigen (1)
Studies
Open first, then newest update. How each study uses Measles-Mumps-Rubella Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and CorporisRecruitingNot applicableAbeer Mohamed Abdelaziz ElkholyNCT07312604Written as Intra-Lesional MMR Immunotherapy
- Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in ChildrenRecruitingPhase 4Laure Pittet, MD-PhDNCT05758532Written as Measles-Mumps-Rubella vaccine (MMR)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06397768Written as Measles, mumps, and rubella vaccine
- Live Vaccines and Innate Immune Training in COPD.CompletedPhase 4Josefin EklöfNCT06257212Written as MMR Vaccine
- Booster Dose of sIPV Co-administered With MMR and HepA-I.CompletedPhase 4Sinovac Biotech Co., LtdNCT06442449Written as MMR
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedPhase 4Liaoning Chengda Biotechnology CO., LTDNCT06331702Written as Measles-Mumps-Rubella Vaccine
- Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated SepsisCompletedPhase 3Louisiana State University Health Sciences Center in New OrleansNCT04475081Written as MMR vaccine
- Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03205371Written as MMR
- Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya VaccineCompletedPhase 2Themis Bioscience GmbHNCT02861586Written as Priorix®
- A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of WartsCompletedNot applicableB.P. Koirala Institute of Health SciencesNCT04428359Written as Measles-Mumps-Rubella Vaccine
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT02184572Written as Priorix
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedPhase 3GlaxoSmithKlineNCT01681992Written as Priorix
- Measles Vaccine in HCWSuspendedPhase 3Kasr El Aini HospitalNCT04357028Written as Measles-Mumps-Rubella Vaccine
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedPhase 4PATHNCT02880865Written as Measles, mumps, rubella vaccine
- Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter WartsCompletedPhase 4Assiut UniversityNCT03183765Written as Measles-Mumps-Rubella Vaccine
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedPhase 3GlaxoSmithKlineNCT01621802Written as Priorix
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT01702428Written as Priorix
- Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxCompletedPhase 3GlaxoSmithKlineNCT00226499Written as Priorix™
- Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital WartsStatus unknownPhase 3Assiut UniversityNCT03853785Written as MMR vaccine
- Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00289783Written as M-M-R II
See all 32 studies that test Measles-Mumps-Rubella Vaccine →
Given in every arm · 29 — Measles-Mumps-Rubella Vaccine is usual care beside what is tested
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06740630Written as MMR vaccine
- A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06693895Written as Measles, mumps, and rubella vaccine
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06806137Written as MMR vaccine
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingPhase 3GlaxoSmithKlineNCT06855160Written as MMR vaccine
- Study of Concomitant Administration of the sIPV and DTaP or MMRNot yet recruitingPhase 4Institute of Medical Biology, Chinese Academy of Medical SciencesNCT06920069Written as MMR Vaccine
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as M-M-R II
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as M-M-R II vaccine
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as M-M-R II vaccine
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as M-M-R II vaccine
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03547271Written as MMR vaccine
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT05084508Written as Measles, mumps, and rubella vaccine
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03537508Written as Measles, mumps, rubella (MMR) vaccine
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedPhase 3Merck Sharp & Dohme LLCNCT03620162Written as M-M-R™ II
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01436396Written as Measles, mumps, and rubella (MMR) vaccine
- Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01411241Written as Measles, mumps, and rubella vaccine
- Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV DrugsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00257127Written as Measles, mumps, and rubella virus vaccine, live
- Baby Vaccine Study (Sched3)CompletedPhase 2University of OxfordNCT02482636Written as Measles/Mumps/Rubella Vaccine (MMR vaccine)
- Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)CompletedPhase 3Merck Sharp & Dohme LLCNCT03239873Written as M-M-R II®
- Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV VaccinesCompletedPhase 3GlaxoSmithKlineNCT00148941Written as M-M-R II
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)CompletedPhase 3MCM Vaccines B.V.NCT01553279Written as MMR Vaccine
Showing 20 of 29.
As the comparator · 12 — what is tested is compared with Measles-Mumps-Rubella Vaccine
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedPhase 3Shanghai Institute Of Biological ProductsNCT06399003Written as GSK MMR Vaccine (PRIORIX)
- Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic AreaCompletedPhase 2Themis Bioscience GmbHNCT03101111Written as MMR-vaccine
- Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMRStatus unknownPhase 4China National Biotec Group Company LimitedNCT04638985Written as MMR
- Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years OldCompletedPhase 3GlaxoSmithKlineNCT01627561Written as Priorix
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00861744Written as M-M-R® II (Merck and Co)
- Homeopathic Vaccine TrialStatus unknownPhase 4McMaster UniversityNCT02825368Written as MMR
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00839917Written as M-M-R™ II and Varivax™
- Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00985153Written as Comparator: M-M-R II
- ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00975507Written as Comparator: M-M-R II
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedPhase 3Merck Sharp & Dohme LLCNCT00984295Written as Comparator: M-M-R II
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedPhase 3Merck Sharp & Dohme LLCNCT00985166Written as Comparator: M-M-R II
- ProQuad Dose Selection Study (V221-011)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00986232Written as Comparator: M-M-R II